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A B S T R A C T
Purpose
Travel distances to care have increased substantially with centralization of complex cancer
procedures at high-volume centers. We hypothesize that longer travel distances are associated
with higher rates of postoperative readmission and poorer outcomes.
Methods
SEER-Medicare patients with bladder, lung, pancreas, or esophagus cancer who were diagnosed
in 2001 to 2007 and underwent extirpative surgery were included. Readmission rates and survival
were calculated using Kaplan-Meier functions. Multivariable negative binomial models were used
to examine factors associated with readmission.
Results
Four thousand nine hundred forty cystectomies, 1,573 esophagectomies, 20,362 lung resections,
and 2,844 pancreatectomies were included. Thirty- and 90-day readmission rates ranged from
13% to 29% and 23% to 43%, respectively, based on tumor type. Predictors of readmission were
discharge to somewhere other than home, longer length of stay, comorbidities, higher stage at
diagnosis, and longer travel distance (P  .001 for each). Patients who lived farther from the index
hospital also had increased emergency room visits and were more likely to be readmitted to a
hospital other than the index hospital (P  .001). Of readmitted patients, 31.9% were readmitted
more than once. Long-term survival was worse and costs of care higher for patients who were
readmitted (P  .001 for all).
Conclusion
The burden of readmissions after major cancer surgery is high, resulting in substantially poorer
patient outcomes and higher costs. Risk of readmission was most strongly associated with length
of stay and discharge destination. Travel distance also has an impact on patterns of readmission.
Interventions targeted at higher risk individuals could potentially decrease the population burden
of readmissions after major cancer surgery.
J Clin Oncol 33:455-464. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Patient travel distances to complex surgical cancer
care have increased substantially over the last two
decades. In a 2009 study examining pancreatectomy
and esophagectomy, we demonstrated a more than
70% increase in patient travel as surgery was central-
ized at high-volume centers, raising the question of
whether travel burden is a barrier to care for some
patients.1 For many patients, travel for a single epi-
sode of care will be feasible, whereas repeated trips
may become a problem. Surgery is often viewed as a
single episode of care, but in reality, complex surgi-
cal procedures often require extended hospital stays
and multiple perioperative clinic visits, amounting
to substantial travel burden for patients and their
caregivers. The impact of travel distance on the
postoperative care experience has not been previ-
ously studied. It is possible that patients may miss
or delay postoperative visits as a result of long
travel distances. Delayed care could increase the
risk of hospital readmission if potentially minor
issues are permitted to escalate (ie, urinary tract
infection escalating to urosepsis). It is also possi-
ble that patients who live far from the operative
(index) hospital may disproportionately use local
emergency rooms (ERs) for postoperative care.
Physicians at a local facility may be unfamiliar
not only with the patient’s specific case, but also
with the broader management issues after com-
plex cancer surgery. As a result, they may be less
comfortable managing these problems in the
outpatient setting, increasing the likelihood
of readmission.
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No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Age, years
Mean 73.9 74.5 73.8 74.1 72.9
SD 5.4 5.6 5.3 5.5 5.1
Range 66-100 66-100 66-96 66-95 66-90
Median 73 74 73 74 72
Q1 70 70 70 70 69
Q3 78 79 77 78 76
66-69 7,390 25 1,139 23 5,070 25 689 24 492 31
70-74 9,579 32 1,463 30 6,680 33 894 31 542 34
75-79 7,877 27 1,335 27 5,445 27 745 26 352 22
 80 4,873 16 1,003 20 3,167 16 516 18 187 12
Sex
Male 16,265 55 3,633 74 10,113 50 1,288 45 1,231 78
Female 13,454 45 1,307 26 10,249 50 1,556 55 342 22
Race
White 26,583 89 4,485 91 18,186 89 2,482 87 1,430 91
African American 1,484 5 200 4 1,046 5 165 6 73 5
Other 1,652 6 255 5 1,130 6 197 7 70 4
Marital status
Married with living partner 18,174 61 3,230 65 12,066 59 1,768 62 1,110 71
All other† 11,545 39 1,710 35 8,296 41 1,076 38 463 29
Residence
Urban 3,673 12 667 14 2,518 12 289 10 199 13
Metro 25,575 86 4,192 85 17,524 86 2,521 89 1,338 85
Rural 469 2 81 2 320 2 33 1 35 2
Dual eligibility (Medicaid), yes 3,240 11 458 9 2,366 12 297 10 119 8
% of patient census tract below
poverty level
Median 7.1 7.1 7.2 6.6 7.1
Q1 3.9 3.9 3.9 3.6 4.1
Q3 13.5 13.5 13.7 12.7 12.8
Stage
Localized 20,384 69 3,862 78 14,465 71 1,195 42 862 55
Node positive 7,874 26 873 18 4,959 24 1,425 50 617 39
Distant 1,461 5 205 4 938 5 224 8 94 6
Charlson comorbidity index
0 13,657 46 2,918 59 8,554 42 1,304 46 881 56
1 9,164 31 1,171 24 6,640 33 913 32 440 28
2 6,898 23 851 17 5,168 25 627 22 252 16
Distance to index hospital, miles
Mean 47.1 59.4 40.0 63.4 71.0
SD 186.4 197.5 173.7 226.0 221.1
Median 10.4 13.6 9.4 13.9 16.8
Q1 4.4 5.2 4.0 5.6 6.4
Q3 29.1 40.7 24.1 40.5 50.2
Yearly procedure volume, No. of
procedures‡
Mean 12.3 7.7 15.2 4.9 3.1
SD 14.4 9.7 15.8 4.0 2.8
Median 8 4 10 3 2
Q1 3 2 5 2 1
Q3 16 10 19 7 4
Patients with at least one complication
during index admission
5,307 18 918 19 3,163 16 686 24 540 34
(continued on following page)
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Hospital readmissions are costly and lead to fragmentation of
care, resulting in poorer clinical outcomes, including greater 1-year
mortality rates and detriment in the timing of and eligibility for rec-
ommended adjuvant therapies.2,3 Hospital readmission rates after
major cancer surgery are high.4-25 The impact of travel distance on
hospital readmissions is unknown. This study examines patterns of
postoperative readmission for four cancers that require complex sur-
gical resections—bladder, esophagus, lung, and pancreas cancer. We
hypothesize that longer travel distances are associated with higher
rates of postoperative readmission and poorer patient outcomes.
METHODS
Data Source
Data for this study were derived from the Surveillance, Epidemiology,
and End Results (SEER)–Medicare linked database, which is a population-
based data source that provides detailed information about 1.6 million Medi-
care beneficiaries with cancer. SEER is a National Cancer Institute registry
program that collects information about cancer site, stage, and histology for
incident cancer cases occurring in the SEER geographic areas. Sixteen SEER
registries participate in the SEER-Medicare linkage, covering approximately
28% of the US population. The data used in this study include incident
cancer cases from January 2001 to December 2007 linked to Medicare
claims through 2009.
Patient Cohort Selection
Patients were included in the study if they were diagnosed with bladder,
lung, pancreas, or esophagus cancer from 2001 to 2007. Patients were excluded
if they were diagnosed at autopsy or by death certificate,  65 years of age at
diagnosis (to ensure claims data available for 12 months before diagnosis to
calculate comorbidity), not continuously enrolled in both Medicare Parts A
and B for 12 months before and after cancer diagnosis, or enrolled in a health
maintenance organization or Medicare Managed Care anytime during 12
months before and after cancer diagnosis (because claims data may not cap-
ture all delivered care for these patients). Finally, the cohort was limited to
patients who underwent major extirpative surgery (Appendix Table A1, online
only) for invasive bladder, esophagus, lung, or pancreas cancer between Janu-
ary 1, 2001, and December 31, 2008. Patients were included if they had claims
with relevant International Classification of Diseases, Ninth Revision, proce-
dure codes in the Medicare Provider Analysis and Review file (26,588 of 29,719
patients) or if they had claims with relevant Healthcare Common Procedure
Coding System codes in the National Claims History file as well as admission
records in the Medicare Provider Analysis and Review file for corresponding
dates (3,131 of 29,719 patients). A flowchart of cohort selection is presented in
Appendix Figure 1 (online only).
Outcomes
The primary outcomes included readmissions to acute care hospitals
within 30 and 90 days of discharge from extirpative surgery (the index dis-
charge). Admissions to acute inpatient rehabilitation facilities were excluded.
Transfer, defined as admission to an acute inpatient facility other than the
index hospital on the same day or day after index discharge, was considered
part of the index admission, and the two admission records were analyzed as
one admission. Many patients were readmitted more than once, but only the
first readmission within 90 days was used for the analysis of factors associated
with readmission. On the basis of the timing of first readmission, patients were
grouped into the following three mutually exclusive groups: no readmission,
30-day readmission, and 31- to 90-day readmission. For all readmitted pa-
tients, the time from index discharge to first readmission, the total number of
readmissions, the total readmission length of stay including all readmissions
within 90 days, and the total number of complications during the 90 days after
index discharge were measured.
Other outcomes measured included short-term mortality (30- and 90-
day), total number of ER visits not resulting in readmission, and total cost of
care including both inpatient and outpatient visits. Overall survival was mea-
sured as the number of months from surgery to death or the study end
(December 31, 2009), whichever came first.














No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Length of stay for index admission, days
Mean 12.5 13.9 10.7 17.4 22.0
SD 12.8 12.2 11.0 14.9 22.2
Median 9 10 8 13 14
Q1 7 8 6 9 11
Q3 13 15 11 20 24
Deaths during index admission 1,394 5 173 4 859 4 192 7 170 11
Discharge destination
Home 23,465 79 3,760 76 16,574 81 2,071 73 1,060 67
SNF 3,903 13 823 17 2,349 12 476 17 255 16
Other§ 2,351 8 357 7 1,439 7 297 10 258 16
Readmission
No readmission 21,815 73 2,910 59 15,898 78 1,921 68 1,086 69
30-day readmission 4,859 16 1,411 29 2,567 13 580 20 301 19
31- to 90-day readmission 3,045 10 619 13 1,897 9 343 12 186 12
Abbreviations: SD, standard deviation; SNF, skilled nursing facility; Q, quartile.
All characteristics are significantly different across disease sites (P  .001 for all), except census tract poverty (P  .018).
†Separated, divorced, or widowed.
‡Statistics are calculated at the patient level. For example, 50% of cystectomy patients had surgery at a hospital that performed four or more cystectomies for
Medicare patients with bladder cancer per year. Mean/median volume at the hospital level is much lower.
§The majority of these patients were transferred to another inpatient facility (eg, rehabilitation, psychiatric, long-term care) from the index admission.
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Covariates
Distance to care was defined as the straight-line distance between patient
and provider, measured in miles.26,27 Patients and providers were geocoded
at the zip code level. Distance was examined in quartile groups. Because
distance to care varies by cancer type, the quartiles were calculated for each
cancer type separately.
Hospital volume, defined as the total number of SEER-Medicare patients
who had extirpative surgery at the same hospital in the same year, was also
calculated for each cancer type and analyzed in quartiles. Statistics for hospital
volume were calculated at the patient level, such that the median value repre-
sents the hospital volume for the 50th percentile of patients, not the volume of
the 50th percentile hospital.
Patient characteristics examined included demographic, socioeco-
nomic, and clinical factors. The rate and number of postoperative compli-
cations, including surgical site infections, urinary tract infections,
pneumonia, sepsis, venous thromboembolic events, and myocardial in-
farction, were also measured.28
Statistical Analysis
Descriptive statistics were reported for all variables and compared across
disease sites. The distribution of travel distance to index hospital was plotted to
illustrate variation in distance to care across SEER region, disease site, and
index hospital volume. Thirty- and 90-day readmission rates were calculated
for each cancer site using Kaplan-Meier estimates accounting for the number
of patients at risk in each time period.
Multivariable negative binomial regression was performed to identify
factors associated with readmissions and calculate incidence rate ratios count-
ing the number of readmissions over days at risk. Patient demographics,
clinical characteristics, and distance to index hospital and hospital volume
were examined. Patients who died during the index admission were excluded
from these analyses, because these patients could not have been readmitted.
Similarly, for the 90-day readmission analysis, patients who did not survive 30
days or were readmitted during the first 30 days were excluded. The main
analysis was performed by pooling all four cancer sites. However, the same
analyses were repeated for each cancer site separately for sensitivity analysis.
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Bladder Lung Pancreas Esophagus
















































































































































Fig 1. (A) Travel distances by SEER region, disease site, and index hospital volume. (B) Travel distances in the Southwest region are presented separately because
of the large difference in range of values compared with other regions. Outlier values are not shown. Horizontal reference line designates 25 miles.
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The outcomes of patients who were readmitted within 90 days were
compared by disease site with the outcomes of patients who were not readmit-
ted. To investigate the association between patient travel and outcomes, the
four cancer types were pooled and the outcomes were examined by distance
quartiles. Survival since surgery was examined using Kaplan-Meier functions.
Total costs of care were calculated as the total charges for all inpatient and
outpatient care during the designated time period. SAS version 9.3 (SAS
Institute, Cary, NC) was used for all statistical analyses. The study was reviewed
and approved by the Institutional Review Board of the University of North
Carolina (Chapel Hill, NC).
RESULTS
Index Hospitalization
Twenty-nine thousand seven hundred nineteen patients were
included in the analysis (4,940 cystectomies, 1,573 esophagectomies,
20,362 lung resections, and 2,844 pancreatectomies; Table 1). Mean
age ranged from 72.9 to 74.5 years for all disease sites. Median length of
stay for the index admission ranged from 8 days for lung resections to
14 days for esophagectomy. One thousand three hundred ninety-four
patients died during the index admission, representing 3.5% of cystec-
tomies, 10.8% of esophagectomies, 4.2% of lung resections, and 6.8%
of pancreatectomies.
Average travel distances for surgery were inversely proportional
to known cancer incidence patterns, ranging from a median of 9.4
miles for lung to a median of 16.8 miles for esophagus (Fig 1). Patient
travel distance increased as index hospital volume increased. Disease
site and hospital volume patterns were the same in all regions; how-
ever, patients in certain regions had much longer average travel dis-
tances. In particular, in the Southwest region (which for these data
include only New Mexico), patient travel was much greater. Presum-
ably as a result, few patients in the Southwest had surgery at the highest
volume hospitals.
Readmissions
Overall, 30- and 90-day readmission rates ranged from 13% and
23% for lung resection to 30% and 43% for cystectomy, respectively
(Fig 2). Primary diagnoses for readmissions were similar at 30 and 90
days and were generally attributable to the prior surgery (Appendix
Table 2, online only). Clinical and sociodemographic factors associ-
ated with readmission at 30 versus 90 days were also similar (Table 2).
Older patients, male patients, and those with more advanced cancer
and more comorbidity were consistently more likely to be readmitted
(P .05 for all). The strongest predictor of readmission, particularly at
30 days, was discharge from index admission to somewhere other than
home (eg, skilled nursing facility, acute rehab; P  .001 for all).
Similarly, longer length of stay was associated with increased risk of
readmission at 30 and 90 days (P  .001). The occurrence of compli-
cations during the index admission was associated with increased risk
of readmission at 90 days (P  .001) but not 30 days. Index hospital
procedure volume was associated with readmission at 30 days (P 
.05) but not 90 days, but the association was not linear. When all
disease sites were analyzed together, distance to care was associated
with 30-day (P  .05), but not 90-day, readmission rates. Patients who
traveled the farthest were the most likely to be readmitted. However,
when each disease site was analyzed separately, this association held
true only for patients with lung cancer (data not shown).
Outcomes
Patients who were readmitted had poorer outcomes than pa-
tients who were never readmitted. Of readmitted patients, 31.9%
(2,542 of 7,904 patients) were readmitted more than once during the
90 days after the index hospitalization (Appendix Table A3, online
only). On average, these 7,904 patients had 1.5 readmissions (range,
one to 10 readmissions) during the 90 days after the index hospitaliza-
tion and spent a total of 11.4 (lung), 13.4 (bladder), 13.8 (pancreas),
and 15.8 (esophagus) readmission days in the hospital. For each tu-
mor type, approximately one third of readmitted patients (30% to
34%) were readmitted to a hospital other than the index hospital.
Median total 90-day costs of care for readmitted patients were sub-
stantially higher than the costs for those who were not readmitted
(bladder, $45,000 v $26,000; esophagus, $65,000 v $40,000; lung,
$44,000 v $26,000; and pancreas, $63,000 v $45,000, respectively; P 
.001 for each). For patients with bladder and lung cancer, 90-day
postdischarge mortality for readmitted patients was 15% and 14%,
respectively, compared with 10% and 9%, respectively, for patients
who were never readmitted (P  .001). In contrast, 90-day postdis-
charge mortality for patients with pancreas and esophagus cancer was
not statistically significantly different for those who were readmitted
compared with those who were not readmitted. However, 1-year
mortality was statistically significantly worse for readmitted patients
than for patients not readmitted for all disease sites (bladder, 40% v
24%; esophagus, 45% v 34%; lung, 33% v 15%; and pancreas, 55% v
37%, respectively; P  .001 for all; Fig 3).
Impact of Travel Distance
Time to readmission was similar regardless of travel distance
(Table 3). Readmission to a hospital other than the index hospital was
highly associated with travel distance, with 59% of patients in the
longest distance quartile readmitted to different hospitals versus only



















15 30 45 60 9075
Bladder: 30 day, 30%; 90 day, 43%
Lung: 30 day, 13%; 90 day, 23%
Pancreas: 30 day, 22%; 90 day, 35%
Esophagus: 30 day, 22%; 90 day, 35%
No. at risk
Bladder 4,767 3,750 3,289 3,043 2,873 2,743 2,628
Lung 19,503 17,636 16,818 16,193 15,715 15,272 14,849
Pancreas 2,652 2,225 2,034 1,922 1,828 1,733 1,655
Esophagus 1,402 1,184 1,080 1,018 961 921 882
Fig 2. Readmission rates by disease site.
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Table 2. Multivariable Analysis of Factors Associated With Readmission at 30 and 90 Days
Factor








Person-Day IRR 95% CI
Age, years
66-69 7,135 0.17 1 5,973 0.13 1
70-74 9,178 0.18 1.06 0.94 to 1.18 7,601 0.14 1.03 0.94 to 1.14
75-79 7,473 0.21 1.23 1.09 to 1.38 6,037 0.15 1.10 0.99 to 1.21
 80 4,539 0.22 1.24† 1.08 to 1.41 3,608 0.15 1.11 0.98 to 1.24
Sex
Male 15,363 0.22 1 12,246 0.15 1
Female 12,962 0.16 0.64 0.59 to 0.70 10,973 0.13 0.89† 0.82 to 0.96
Race
White 25,368 0.20 1 20,744 0.14 1
African American 1,385 0.18 0.93 0.7 to 1.14 1,148 0.16 1.07 0.91 to 1.26
Other 1,572 0.16 0.78‡ 0.64 to 0.95 1,327 0.13 0.86 0.73 to 1.02
Marital status
Married with living partner 17,352 0.19 1 14,247 0.14 1
All other 10,973 0.19 1.01 0.92 to 1.10 8,972 0.14 0.91‡ 0.84 to 0.98
Residence
Urban 3,491 0.20 0.97 0.84 to 1.12 2,825 0.15 1.07 0.95 to 1.21
Metro 24,386 0.19 1 20,048 0.14 1
Rural 447 0.26 1.43‡ 1.04 to 1.98 345 0.14 0.93 0.69 to 1.28
Dual eligibility (Medicaid)
No 25,279 0.19 1 20,787 0.14 1
Yes 3,046 0.22 1.18‡ 1.03 to 1.37 2,432 0.16 1.11 0.98 to 1.26
Stage
Localized 19,565 0.18 1 16,198 0.12 1
Node positive 7,409 0.21 1.12‡ 1.02 to 1.23 5,991 0.19 1.59 1.48 to 1.72
Distant 1,351 0.25 1.44 1.20 to 1.74 1,030 0.24 1.95 1.69 to 2.24
No. of complications (continuous) 1.03 0.98 to 1.09 1.08 1.03 to 1.12
Length of stay, days (continuous) 1.03 1.03 to 1.04 1.01 1.01 to 1.01
Modified Charlson score
0 13,217 0.17 1 11,114 0.12 1
1 8,689 0.19 1.13‡ 1.03 to 1.25 7,157 0.14 1.09 1.00 to 1.19
2 6,419 0.25 1.46 1.32 to 1.63 4,948 0.19 1.42 1.30 to 1.55
Discharge destination
Home 23,457 0.17 1 19,804 0.13 1
SNF 3,898 0.31 1.61 1.42 to 1.81 2,819 0.21 1.46 1.32 to 1.62
Other 970 0.41 3.25 2.54 to 4.16 596 0.27 1.62 1.35 to 1.93
% census tract below poverty
Highest ( 75%) 6,879 0.20 1 5,612 0.16 1
Quartile 2 6,920 0.20 1.05 0.93 to 1.18 5,621 0.14 0.91 0.82 to 1.01
Quartile 3 6,982 0.19 1.00 0.88 to 1.14 5,761 0.14 0.90 0.81 to 1.01
Lowest ( 25%) 7,006 0.19 1.02 0.89 to 1.16 5,798 0.14 0.93 0.83 to 1.04
Hospital volume quartile
Lowest 7,269 0.18 1 6,020 0.14 1
Quartile 2 6,820 0.21 1.25 1.11 to 1.41 5,504 0.13 0.98 0.89 to 1.09
Quartile 3 7,208 0.19 1.15‡ 1.02 to 1.29 5,922 0.14 1.06 0.95 to 1.17
Highest 7,028 0.20 1.26 1.12 to 1.43 5,773 0.15 1.09 0.99 to 1.21
Distance to hospital quartile
Nearest 7,004 0.18 1 5,803 0.15 1
Quartile 2 7,063 0.19 1.14‡ 1.01 to 1.28 5,793 0.14 0.96 0.86 to 1.06
Quartile 3 7,091 0.19 1.12 1.00 to 1.27 5,822 0.14 0.96 0.86 to 1.06
Farthest 7,105 0.21 1.27 1.12 to 1.45 5,748 0.14 0.94 0.84 to 1.05
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Patients who traveled longer distances generally had lower
short-term mortality than patients who traveled shorter distances
(Table 3). Accordingly, patients who lived farther from the index
hospital had lower rates of complications during the index admis-
sion. However, recorded complications during the 90 days after
discharge from the index admission did not vary based on travel
distance to index hospital. Although no difference in postdischarge
complication rates was noted, patients who lived farther from the
index hospital had consistently higher rates of ER visits than
those who had surgery closer to home. Eight percent of patients
in the shortest travel quartiles had at least one ER visit by 30 days
compared with 12% of patients in the longest travel quartile
(P  .001); at 90 days, these differences persisted (14% v 20%,
respectively; P  .001). Although patients in the longest travel
groups had slightly higher readmission rates, among readmitted
patients, the total number of readmission days spent in the
hospital was greater for patients who lived closer to the index
hospital (P  .004). Long-term overall survival was not differ-
ent across distance groups.
DISCUSSION
Readmission rates after major cancer surgery are high. In this study,
depending on cancer site, 20% to 50% of patients older than age 65
years were readmitted during the 90 days after discharge from the
surgical admission. The precise burden of postoperative readmissions
is difficult to measure because there is no standard methodology for
defining readmission after cancer surgery. Varying time periods from
30 days to 1 year have been used to try to capture readmissions, and
using secondary data, it is challenging to determine whether a hospital
admission is a readmission (attributable to the index admission and
potentially avoidable) or rather a separate index admission attribut-
able to cancer progression or other comorbid medical conditions.
This study suggests that the bulk of readmissions up to 90 days are
attributable to the surgical intervention. The rate of readmission
tapers at 20 days and further after 40 days, but a substantial portion
of readmissions still occurs after this time period. Studies aimed at
qualitatively studying readmissions may be able to focus on shorter






















No readmission 2,738 1,853 1,106 618
30 day 1,410 727 413 235
31-90 day 619 262 146 76
BA
0 20 40 60
Log-rank P < .001
No readmission, 5-year survival, 48%
30-day readmission, 5-year survival, 37%






















No readmission 15,039 12,254 7,554 4,118
30 day 2,567 1,440 835 415
31-90 day 1,897 1,092 604 325
0 20 40 60
Log-rank P < .001
No readmission, 5-year survival, 55%
30-day readmission, 5-year survival, 33%






















No readmission 1,729 889 410 193
30 day 580 204 82 37
31-90 day 343 93 33 17
DC
0 20 40 60
Log-rank P < .001
No readmission, 5-year survival, 25%
30-day readmission, 5-year survival, 16%






















No readmission 916 608 332 180
30 day 301 144 76 42
31-90 day 185 79 43 19
0 20 40 60
Log-rank P < .001
No readmission, 5-year survival, 43%
30-day readmission, 5-year survival, 31%
31- to 90-day readmission, 5-year survival, 26%
Fig 3. Kaplan-Meier estimates of survival by readmission group for (A) bladder cancer, (B) lung cancer, (C) pancreas cancer, and (D) esophagus cancer.
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Quartile of Distance to Index Hospital
P
Quartile 1:






Farthest (n  7,397)
No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Time to readmission, days .299
Mean 29.15 29.97 28.76 29.37 28.55
SD 25.67 25.67 25.33 25.83 25.85
Median (Q1, Q3) 20 22 20 20 19
Q1 7 8 7 8 7
Q3 47 48 45 47 46
Readmission to index hospital  .001
No 2,604 33 219 11 394 20 777 39 1,214 59
Yes 5,285 67 1,696 89 1,561 80 1,196 61 832 41
90-day mortality 2,969 10 860 12 748 10 672 9 689 9  .001
1-year mortality 7,084 24 1,914 26 1,761 24 1,687 23 1,722 23  .001
Complications during index
admission, No.
Mean 0.31 0.34 0.32 0.30 0.29 .001
SD 0.87 0.90 0.87 0.85 0.86
0 24,358 82 5,985 81 6,029 81 6,141 83 6,203 84  .001
 1 5,295 18 1,447 19 1,392 19 1,262 17 1,194 16
Complications in 90 day after
index discharge, No.
Mean 0.32 0.29 0.33 0.32 0.33 .085
SD 1.04 0.95 1.05 1.07 1.08
0 25,625 86 6,450 87 6,389 86 6,433 87 6,353 86 .190
 1 4,028 14 982 13 1,032 14 970 13 1,044 14
No. of ER visits in 30 days
Mean 0.11 0.10 0.08 0.12 0.14  .001
SD 0.37 0.37 0.31 0.39 0.41
Range 0-10 0-10 0-5 0-7 0-7
0 26,919 91 6,824 92 6,901 93 6,678 90 6,516 88  .001
 1 2,734 9 608 8 520 7 725 10 881 12
No. of ER visits in 90 days
Mean 0.21 0.19 0.16 0.22 0.27  .001
SD 0.62 0.70 0.47 0.59 0.69
Range 0-38 0-38 0-6 0-13 0-18
0 24,923 84 6,359 86 6,443 87 6,198 84 5,923 80  .001
 1 4,730 16 1,073 14 978 13 1,205 16 1,474 20
Total No. of readmissions
within 90 days
Mean 0.39 0.37 0.38 0.39 0.41 .003
SD 0.77 0.74 0.75 0.77 0.80
0 21,763 73 5,517 74 5,466 74 5,429 73 5,351 72 .034
1 5,352 18 1,339 18 1,325 18 1,334 18 1,354 18
 2 2,538 9 576 8 630 8 640 9 692 9
Total readmission length of stay
within 90 days, days
.004
Mean 27.00 28.06 27.38 26.99 25.68
SD 21.33 20.40 21.27 22.41 21.12
Median 21 22 21 20 19
Q1 14 15 14 14 14
Q3 32 34 32 31 30
Overall survival, months .150
Mean 36.18 35.81 36.37 36.69 35.85
SD 27.58 28.33 27.80 27.10 27.08
Median 31 30 32 32 31
Q1 13 11 13 14 13
Q3 55 56 54 55 54
Abbreviations: ER, emergency room; SD, standard deviation; Q, quartile.
Calculated for readmission patients only.
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studies aimed at quantifying the burden of readmissions attributable to
cancer surgery should consider a longer postoperative time window, be-
cause a large portion of readmissions occurs after 30 days.
Hospitalreadmissionsarecostlyandhavebeenviewedasamarkerof
inferior quality of care in broader clinical contexts. In general, patients
who are readmitted have poorer short- and long-term outcomes. As a
result, investigators have sought to identify risk factors for readmission as
a critical step toward the development of targeted interventions aimed at
decreasing readmissions.4,9-25 For cancer surgery, the most consistent risk
factors for readmission are strikingly similar across tumor types and in-
clude patient comorbidity,4,13,16,18-22,25 occurrence of postoperative
complications during index admission,9,11,12,16,17,21,22 and extended
length of stay of index admission.4,11,12,14-16,20-22 Extended length of
stay and discharge to a destination other than home,17,25 which were
strong risk factors for readmission in this study, are both likely proxies
for poor performance status. Consequently, efforts to minimize read-
missions may best be directed toward patients with a complex index
hospital stay and those with poor performance status preoperatively
or at the time of discharge from the index hospitalization.
Because complex cancer surgery often requires longer hospital-
izations and multiple perioperative visits, we hypothesized that travel
burden could be a barrier to postoperative care for some patients. In
this study, patients who traveled long distances had better immediate
postoperative outcomes than patients who traveled short distances to
the operative hospital. This is a result of the high correlation between
longer travel distances and higher hospital volume. However, al-
though postdischarge rates of complications were the same across
travel distance groups, patients who traveled long distances to the
operative hospital had higher rates of readmission and substantially
higher rates of ER visits than patients who had surgery close to home.
The latter finding suggests that patients who live far from the surgeon
are more likely to use the ER for smaller postoperative issues that do
not require readmission rather than travel long distances to the sur-
geon’s office for evaluation.
Travel distance was also associated with the location of readmis-
sion, with patients who lived far from the index hospital being much
more likely to seek postoperative care at a hospital closer to their
home. The consequences of readmission to a hospital other than the
index hospital are unknown. However, it can be presumed that this
trend would lead to further increases in cost and fragmentation of
care as additional providers who are unfamiliar with the patient,
procedure, and plan of care are added to the treatment team.
Additional studies are needed to determine the relationship be-
tween the location of readmission and the costs and outcomes of
postoperative cancer care.
This study examined only patients with continuous Medicare
coverage throughout their initial diagnosis and treatment for cancer.
The findings from this older population may not completely reflect
patterns of care and readmission for younger populations or for those
with no or different health coverage. Older patients are more likely to
have increased comorbidity and are also, in general, less willing to
travel longer distances for care, both of which could influence
patterns of readmission. In addition, although travel patterns are
similar throughout the country, the burden of travel is certainly
more substantial in some areas than others. In this study, this is
most evident in the Southwest region of the United States, where
travel distances for this small sample were five- to 10-fold greater
than in other parts of the country. Consequently, there may be a
differential impact of travel distance in the different regions of the
country; however, further exploration of this was beyond the scope
of the current study.
Travel distance impacts the patterns and burden of readmission
after major cancer surgery. The negative impact of long patient travel
distances does not seem to outweigh the benefits of having surgery at a
high-volume center. However, travel distance needs to be acknowl-
edged as a potential barrier to high-quality care. Future research into
models of cancer care delivery should focus on interventions that
can mitigate the negative consequences of patient travel. Multilevel
interventions, targeted at higher risk patients, will be necessary to
decrease the population burden of readmissions after cancer sur-
gery on a large scale.
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Appendix
Table A1. Codes Used to Identify Extirpative Procedures
Cancer
Type ICD-9 Procedure Code HCPCS code
Bladder 57.7 Total cystectomy
57.71 Radical cystectomy
57.79 Other total cystectomy
51570 Removal of bladder
51575 Removal of bladder and nodes
51580 Removal of bladder/revise tract
51585 Removal of bladder and nodes
51590 Removal of bladder/revise tract
51595 Removal of bladder/revise tract
51596 Removal of bladder/create pouch
51597 Removal of pelvic structures
Lung 32.4 Lobectomy of lung
32.41 Thoracoscopic lobectomy of lung
32.49 Other lobectomy of lung
32.5 Pneumonectomy
32.50 Thoracoscopic pneumonectomy
32.59 Other and unspecified pneumonectomy
32440 Removal of lung
32442 Sleeve pneumonectomy
32445 Removal of lung




32503 Resect apical lung tumor
32504 Resect apical lung tumor/chest
32663 Thoracoscopy surgical
Pancreas 52.5 Partial pancreatectomy
52.51 Proximal pancreatectomy
52.52 Distal pancreatectomy
52.53 Radical subtotal pancreatectomy
52.59 Other partial pancreatectomy
52.6 Total pancreatectomy
52.7 Radical pancreaticoduodenectomy
48140 Partial removal of pancreas
48145 Partial removal of pancreas
48146 Pancreatectomy
48148 Removal of pancreatic duct




48155 Removal of pancreas
48160 Pancreas removal/transplantation
Esophagus 42.4 Excision of esophagus
42.40 Esophagectomy, not otherwise specified
42.41 Partial esophagectomy
42.42 Total esophagectomy
43.5 Partial gastrectomy with anastomosis to esophagus
43.99 Other total gastrectomy
43107 Removal of esophagus
43108 Removal of esophagus
43112 Removal of esophagus
43113 Removal of esophagus
43116 Partial removal of esophagus
43117 Partial removal of esophagus
43118 Partial removal of esophagus
43121 Partial removal of esophagus
43122 Partial removal of esophagus
43123 Partial removal of esophagus
43124 Removal of esophagus
Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision; HCPCS, Healthcare Common Procedure Coding System.
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Table A2. Primary Admitting Diagnosis for Readmission
Admitting Diagnosis
% of Patients

















Volume depletion 8.8 5.7 3.1 9.0 7.9 6.0 8.1
Dyspnea 11.2 6.9 7.7 4.3
Abdominal pain 5.3 4.7 9.3 8.2
Pneumonia 8.4 6.4 3.5 9.3 7.0
Urinary tract infection 7.7 7.1
Nausea and vomiting 9.2 2.9 5.0 5.4
Fever 6.8 5.8 4.8 3.5
Chest pain 5.2 4.8 4.3
Atrial fibrillation/flutter 2.9
Postoperative infection 8.1 4.7
Intestinal obstruction 5.3
Congestive heart failure 2.7 2.5
Septicemia 5.2
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No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Total No. of readmissions within 90 days
Mean 1.5 1.5 1.4 1.5 1.5
SD 0.8 0.8 0.8 0.9 0.8
Median 1 1 1 1 1
Q1 1 1 1 1 1
Q3 2 2 2 2 2
1 5,362 68 1,284 63 3,170 71 595 64 313 64
 2 2,542 32 746 37 1,294 29 328 36 174 36
Time to readmission, days
Mean 29.1 25.0 31.2 29.0 28.2
SD 25.7 23.2 26.5 26.0 25.5
Median 20 16 23 20 20
Q1 7 7 8 7 6
Q3 47 37 51 48 46
Readmission to index hospital
No 2,606 33 615 30 1,510 34 314 34 167 34
Yes 5,298 67 1,415 70 2,954 66 609 66 320 66
Length of stay, days
Mean 14.5 14.4 12.5 18.9 25.1
SD 13.3 10.9 11.5 14.4 23.7
Median 10 11 9 15 17
Q1 8 9 7 10 12
Q3 16 16 14 22 29
Length of stay during first readmission,
days
Mean 8.7 8.7 8.3 9.4 10.9
SD 9.8 10.2 9.3 10.1 12.2
Median 6 6 6 6 7
Q1 4 4 4 4 4
Q3 10 10 9 11 13
Total length of stay within 90 days,
including index admission, days
Mean 27.0 27.8 23.9 32.6 40.9
SD 21.3 19.9 19.3 21.7 32.5
Median 21 22 18 27 30
Q1 14 16 12 18 20
Q3 32 32 28 39 52
Total readmission length of stay
after index discharge, days
Mean 12.5 13.4 11.4 13.8 15.8
SD 14.1 15.1 13.2 14.2 16.9
Median 8 9 7 9 10
Q1 4 5 4 5 5
Q3 15 16 14 18 20
No. of ER visits not resulting in
readmission within 30 days
0 6,776 86 1,755 86 3,866 87 767 83 388 80
1 1,128 14 275 14 598 13 156 17 99 20
No. of ER visits not resulting in
readmission within 90 days
Mean 0.4 0.3 0.3 0.5 0.6
SD 0.9 1.1 0.7 1.0 1.0
Median 0 0 0 0 0
Q1 0 0 0 0 0
Q3 1 0 1 1 1
0 5,856 74 1,555 77 3,347 75 635 69 319 66
1 2,048 26 475 23 1,117 25 288 31 168 34
(continued on following page)
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No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Distance to index hospital, miles
Mean 48.2 53.1 44.4 53.2 53.2
SD 177.0 163.3 187.0 178.6 127.3
Median 11.3 13.8 10.1 12.8 17.2
Q1 4.8 5.4 4.2 5.5 5.9
Q3 32.4 39.8 26.8 37.3 46.5
 15 4,531 57 1,055 52 2,752 62 495 54 229 47
 15 3,358 42 971 48 1,701 38 428 46 258 53
Distance to first readmission hospital,
miles
Mean 35.8 38.2 33.9 35.3 43.4
SD 166.8 156.1 177.7 148.0 138.8
Median 7.2 8.1 6.7 7.8 8.8
Q1 3.2 3.6 2.9 3.5 3.8
Q3 16.3 19.8 14.4 16.9 24.7
 15 5,728 72 1,379 68 3,372 76 661 72 316 65
 15 2,144 27 645 32 1,069 24 260 28 170 35
Total costs within 90 days, US$
Mean 58,704.4 54,278.4 54,001.0 73,419.1 92,377.9
SD 47,760.7 39,380.7 40,953.6 47,267.1 95,634.3
Median 46,869.2 44,740.9 43,466.5 62,123.8 64,459.5
Q1 34,928.3 33,656.6 33,167.9 47,042.2 46,495.4
Q3 65,841.7 62,663.7 59,931.4 83,793.0 101,988.8
Discharge destination from index
admission
Home 5,944 75 1,531 75 3,431 77 662 72 320 66
SNF 1,532 19 412 20 791 18 212 23 117 24
Other 428 5 87 4 242 5 49 5 50 10
Discharge destination from readmission
Home 5,696 72 1,447 71 3,291 74 655 71 303 62
SNF 1,253 16 341 17 654 15 155 17 103 21
Other 940 12 240 12 509 11 111 12 80 16
Time from surgery discharge to study
end or death, months
Mean 28.3 27.9 31.0 18.0 25.3
SD 26.3 26.9 26.8 19.6 26.2
Median 21 19 25 10 15
Q1 6 5 7 4 4
Q3 44 43 48 25 39
Abbreviations: ER, emergency room; SD, standard deviation; SNF, skilled nursing facility; Q, quartile.
Patterns of Postoperative Cancer Readmissions
www.jco.org © 2014 by American Society of Clinical Oncology
Diagnosed with bladder, lung, pancreas,
or esophagus cancer
(N = 387,641)




Age at diagnosis ≥ 66 years
(n = 295,341)
Continuous enrollment in Medicare A+B
for 12 months before and after diagnosis
(n = 282,619)
No HMO/Medicare Managed Care for
12 months before and after diagnosis
(n = 223,076)
Diagnoses before 2000 or invalid date
(n = 8,553)
Diagnosed at autopsy/by death certificate
(n = 7,431)
Diagnosed before age 66 years
(n = 76,316)
No continuous enrollment in Medicare A+B
(n = 12,722)
No continuous enrollment in
HMO/Medicare Managed Care
(n = 59,543)
Had invasive cancer and surgery 
between diagnosis and 12/31/2008
(n = 29,719)
Did not have surgery between diagnosis 
and 12/31/2008 or had a noninvasive cancer
(n = 193,357)
Fig A1. Patient cohort selection. HMO, health maintenance organization.
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